Division of Hematology, Department of Medicine, Tokyo, Japan.
Center for Transfusion Medicine and Cell Therapy, Keio University School of Medicine, Tokyo, Japan.
J Infect Dis. 2019 Aug 9;220(6):1001-1007. doi: 10.1093/infdis/jiz237.
Human herpesvirus 6 (HHV-6) causes life-threatening central nervous system disorders after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent studies implicated CD134 as a specific receptor of HHV-6B and demonstrated that its expression levels in CD4-positive T cells after allo-HSCT could be related to the reactivation of HHV-6. We prospectively evaluated the relationship between HHV-6 reactivation and CD134+ T cells in the recipients of allo-HSCT.
HHV-6 viral load in plasma was quantitatively measured weekly after allo-HSCT by digital polymerase chain reaction in 34 patients. The ratio of CD134 in CD4+ T cells (CD134/CD4 ratio) was serially measured by flow cytometry before and after transplantation.
HHV-6 reactivation was detected in 23 patients (68%). The CD134/CD4 ratio before conditioning was significantly higher in patients with HHV-6 reactivation than in those without (median, 3.8% vs 1.5%, P < .01). In multivariate analysis, a higher CD134/CD4 ratio before conditioning was significantly associated with the incidence of HHV-6 reactivation (odds ratio, 10.5 [95% confidence interval, 1.3-85.1], P = .03).
A higher CD134/CD4 ratio before conditioning was associated with a higher risk of HHV-6 reactivation, suggesting that the rate may be a promising marker for predicting HHV-6 reactivation after allo-HSCT.
人类疱疹病毒 6 型(HHV-6)可导致异基因造血干细胞移植(allo-HSCT)后危及生命的中枢神经系统疾病。最近的研究表明 CD134 是 HHV-6B 的特异性受体,并证明 allo-HSCT 后 CD4 阳性 T 细胞中 CD134 的表达水平可能与 HHV-6 的再激活有关。我们前瞻性评估了 allo-HSCT 受者中 HHV-6 再激活与 CD134+T 细胞之间的关系。
通过数字聚合酶链反应在 34 例患者中每周定量测量 allo-HSCT 后血浆中的 HHV-6 病毒载量。在移植前后通过流式细胞术连续测量 CD4+T 细胞中 CD134 的比例(CD134/CD4 比值)。
23 例患者(68%)检测到 HHV-6 再激活。与未发生 HHV-6 再激活的患者相比,发生 HHV-6 再激活的患者预处理前的 CD134/CD4 比值明显更高(中位数分别为 3.8%和 1.5%,P <.01)。在多变量分析中,预处理前较高的 CD134/CD4 比值与 HHV-6 再激活的发生率显著相关(优势比,10.5[95%置信区间,1.3-85.1],P =.03)。
预处理前较高的 CD134/CD4 比值与 HHV-6 再激活的风险增加相关,表明该比率可能是预测 allo-HSCT 后 HHV-6 再激活的有前途的标志物。